Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 16/20 | 0.76 |
| ▸ | BCL2 | P10415 | 17/20 | 0.75 |
| ▸ | BAD | Q92934 | 4/20 | 0.75 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.75 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.75 |
| ▸ | ASPH | Q12797 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29077589 | 0.91 | BCL2 (0.79) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19244593 | 0.91 | BCL2 (0.76) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19503725 | 0.90 | BCL2 (0.62) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL22295589 | 0.90 | BCL2 (0.62) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL25646590 | 0.90 | BCL2 (0.82) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19014640 | 0.90 | BCL2 (0.61) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL7791088 | 0.89 | BCL2L1 (0.85) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL20812412 | 0.89 | BCL2L1 (0.87) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL21982308 | 0.89 | BCL2 (0.82) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL27047632 | 0.89 | BAD (0.76) | BCL2L1BCL2BADBCL2L2BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319316-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BIOVENTURES, LLC | 2020-10-22 | — | — | US | disclosed |
| EP-3689886-A1 | BCL-2/BCL-XL INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | The Regents of The University of Michigan (US) | 2020-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BCL2, BAX, BCL2L1 | BCL2L1 3/4885BCL2 1/4885BAD 11/4885 |
| US-11319316-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BCL2, BAX, BCL2L1 | BCL2L1 3/4885BCL2 1/4885BAD 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.